Secondary effects associated with treatment of atopic dermatitis with tacrolimus ointment: The geneva experience;Effets secondaires lors du traitement de la dermatite atopique par tacrolimus topique (FK 506): L'expérience genevoise

Medecine et Hygiene

Volumn 59, Issue 2345, 2001, Pages 1011-1013

  Tschanz, Christophe ^a   Lübbe, Jann ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION PREVENTION; MALE; OINTMENT; SHORT SURVEY; SKIN INFECTION; SKIN IRRITATION;

EID: 0343371809     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Kino T, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. J Antibiot 1987; 40: 1249-55.
2. Nagakawa H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1944; 344: 883.
3. Aoyama H, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0,1% FK-506 ointment. Br J Dermatol 1995; 133: 494-6.
4. Ruzicka T, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. W Engl J Med 1997; 337: 816-21.
5. Alaiti S, et al. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
6. Boguniewicz M, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44.
7. Reitamo S, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006.
8. Soter N, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II. safety. J Am Acad Dermatol 2001; 44 (Suppl. 1): S39-S46.
9. Paller A, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (Suppl 1): S47-S57.
10. Kang S, et al. Long-term safety and afficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (Suppl. 1): S58-S64.
11. Drake L, et al. The impact of tacrolimus ointment on health-related quality of life of adult pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44 (Suppl. 1): S65-S72.
12. Aoyama H, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0,1% FK-506 ointment. Br J Dermatol 1995; 133: 494-6.
13. Bieber T. Topical tacrolimus (FK-506): A new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102: 555-7.
14. Bos J, Meinardi M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9: 165-9.
15. Kawashima M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996; 348: 1240-1.
16. Rizicha T, et al. Tacrolimus the drug for the turn of the century? Arch Dermatol 1999; 135: 574-80.
17. Poumaras CC, et al. Staphylococcal colonization dynamics in atopic dermatitis lesional skin during topical treatment with tacrolimus (FK-506) 0,1% JEAD 2000; 14 (Suppl. 1): S126.
18. Bork K, et al. Increasing incidence of eczema herpeticum: Analysis of seventy-five cases. J Am Acad Dermatol 1988; 19: 1024-9.
19. Glodman BD. Herpes serology for dermatologists. Arch Dermatol 2000; 136: 1158-61.
20. Koelle DM, et al. Herpes simplex virus : The importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45: 1-8.